Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures (Dollars in Millions Except Per Share Data) 2021 2020 2021 2020 Net Earnings, after tax- as reported $4,736 $1,738 $20,878 $14,714 Pre-tax Adjustments Intangible Asset Amortization expense 1,121 1,234 4,697 4,660 Litigation expense, net 274 2,902 2,328 5,112 IPR&D - 37 900 181 Restructuring related 140 85 473 448 Acquisition, integration and divestiture related ยน 26 14 (478) (1,073) (Gains)/losses on securities (198) (373) (533) (547) Medical Device Regulation 73 55 234 144 Consumer Health separation costs 67 - 67 - Other - - - 6 Tax Adjustments Tax impact on special item adjustments 2 (184) (606) (1,281) (1,608) Tax legislation and other tax related (377) (121) (1,090) (604) Adjusted Net Earnings, after tax $5,678 $4,965 $26,195 $21,433 Average shares outstanding (Diluted) 2,670.2 2,669.2 2,674.0 2,670.7 Adjusted net earnings per share (Diluted) $2.13 $1.86 $9.80 $8.03 Operational adjusted net earnings per share (Diluted) $2.18 $9.65 Notes: 1 2 The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax special items in arriving at adjusted earnings. Fourth Quarter Twelve Months Ended Acquisition, integration and divestiture related for 2021 primarily includes the gain on the divestiture of two Pharmaceutical brands outside of the U.S. Acquisition, integration and divestiture related for 2020 primarily includes a Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated with the Auris Health acquisition. -- 1 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported 1.1% 16.5% 4.1% 10.4% U.S. 1.3% 4.2% 1.0% 3.0% International 0.9% 33.4% 7.0% 18.5% WW Currency (0.7) (1.4) (1.2) (1.2) U.S. - - - - International (1.2) (3.5) (2.3) (2.7) WW Operational 1.8% 17.9% 5.3% 11.6% U.S. 1.3% 4.2% 1.0% 3.0% International 2.1% 36.9% 9.3% 21.2% General Surgery Advanced Sterilization Products 0.3 0.1 U.S. 0.0 0.0 International 0.5 0.2 Skin Health / Beauty Dr. Ci Labo - Sedona 0.7 0.1 U.S. 0.0 0.0 International 1.2 0.3 All Other Acquisitions and Divestitures 0.4 0.7 0.1 0.4 U.S. 0.6 0.0 0.2 0.1 International 0.3 1.7 0.0 0.8 WW Adjusted Operational 2.9% 18.6% 5.6% 12.3% U.S. 1.9% 4.2% 1.2% 3.1% International 3.6% 38.6% 9.8% 22.4% Adjusted Operational Sales Growth FOURTH QUARTER 2021 ACTUAL vs. 2020 ACTUAL Segments Note: Percentages are based on actual, non-rounded figures and may not sum -- 2 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measure Consumer Health Pharmaceutical Medical Devices Total WW As Reported 4.1% 14.3% 17.9% 13.6% U.S. 2.4% 8.6% 14.9% 9.3% International 5.6% 21.6% 20.6% 18.2% WW Currency 1.3 1.2 1.7 1.4 U.S. - - - - International 2.5 2.8 3.3 2.9 WW Operational 2.8% 13.1% 16.2% 12.2% U.S. 2.4% 8.6% 14.9% 9.3% International 3.1% 18.8% 17.3% 15.3% General Surgery Advanced Sterilization Products 0.5 0.1 U.S. 0.0 0.0 International 1.0 0.3 Skin Health / Beauty Dr. Ci Labo - Sedona 0.5 0.1 U.S. 0.0 0.0 International 1.0 0.2 All Other Acquisitions and Divestitures 0.4 0.5 0.1 0.4 U.S. 0.6 0.0 0.4 0.2 International 0.3 1.4 0.0 0.8 WW Adjusted Operational 3.8% 13.6% 16.8% 12.8% U.S. 3.0% 8.6% 15.3% 9.5% International 4.4% 20.2% 18.3% 16.6% Note: Percentages are based on actual, non-rounded figures and may not sum Adjusted Operational Sales Growth TWELVE MONTHS 2021 ACTUAL vs. 2020 ACTUAL Segments -- 3 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Reported Income/(loss) Before Tax by Segment $ 338 (2,057) 4,343 3,675 575 363 (420) (334) 4,836 1,647 % to Sales 9.2% -56.9% 30.4% 30.0% 8.4% 5.5% -1.7% -1.5% 19.5% 7.3% Intangible asset amortization expense 100 109 761 868 260 257 - - 1,121 1,234 In-process research and development - - - 10 - 27 - - - 37 Litigation related 122 2,762 (35) (172) 187 312 - - 274 2,902 Loss/(gain) on securities 1 - (237) (368) 38 (5) - - (198) (373) Restructuring related 28 (1) 22 24 90 62 - - 140 85 Acquisition, integration and divestiture related - - 5 - 21 14 - - 26 14 Medical Device Regulation - - - - 73 55 - - 73 55 Consumer Health separation costs 67 - - - - - - - 67 - Other - - - - - - - - - - Adjusted Income Before Tax by Segment $ 656 813 4,859 4,037 1,244 1,085 (420) (334) 6,339 5,601 % to Sales 17.9% 22.5% 34.0% 32.9% 18.1% 16.5% -1.7% -1.5% 25.6% 24.9% *Estimated as of 1/25/2022 Q4 QTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 4 of 6 -- Johnson & Johnson and Subsidiaries Reconciliation of Non-GAAP Financial Measures 2021 2020 2021 2020 2021 2020 2021 2020 2021 2020 Reported Income/(Loss) Before Tax by Segment $ 1,294 (1,064) 18,181 15,462 4,373 3,044 (1,072) (945) 22,776 16,497 % to Sales 8.8% -7.6% 34.9% 33.9% 16.2% 13.3% -1.1% -1.1% 24.3% 20.0% Intangible asset amortization expense 414 415 3,258 3,246 1,025 999 - - 4,697 4,660 In-process research and development - 10 900 171 - - 900 181 Litigation related 1,603 3,931 640 834 85 347 - - 2,328 5,112 Loss/(gain) on securities (18) - (486) (545) (29) (2) - - (533) (547) Restructuring related 119 68 76 94 278 286 - - 473 448 Acquisition, integration and divestiture related - (562) 20 84 (1,093) - - (478) (1,073) Medical Device Regulation - - - 234 144 - - 234 144 - Consumer Health separation costs 67 - - - - - - 67 - Other - - - - - 6 - - - 6 Adjusted Income Before Tax by Segment $ 3,479 3,350 21,107 19,121 6,950 3,902 (1,072) (945) 30,464 25,428 % to Sales 23.8% 23.8% 40.5% 42.0% 25.7% 17.0% -1.1% -1.1% 32.5% 30.8% *Estimated as of 1/25/2022 Q4 YTD - Income Before Tax by Segment* Dollars in Millions Consumer Health Pharmaceutical Medical Devices Unallocated Worldwide Total -- 5 of 6 -- Fourth Quarter Fourth Quarter Jan. 2, 2022 GAAP Intangible asset amortization Litigation expense, net Restructuring related Medical Device Regulation Other Jan. 2, 2022 Non-GAAP Cost of products sold 7,955 $ (1,111) (21) (26) 6,797 Selling, marketing and admin expenses 7,154 (7) 7,147 Research and development expense 4,720 - (40) 4,680 Other (Income) / Expense 9 (10) (274) (36) (26) 198 (67) - (206) In-process research and development - - - Restructuring 83 (83) - Provision for taxes on income 100 162 49 - 27 6 (89) 14 15 377 - 661 Net Earnings 4,736 959 225 - 113 20 (109) 59 52 (377) - 5,678 Fourth Quarter Fourth Quarter Jan. 3, 2021 GAAP Intangible asset amortization Litigation expense, net Restructuring related Medical Device Regulation Other Jan. 3, 2021 Non-GAAP Cost of products sold 7,814 $ (1,225) (20) (19) 6,550 Selling, marketing and admin expenses 6,457 (7) 6,450 Research and development expense 4,032 - (29) 4,003 Other (Income) / Expense 2,354 (9) (2,902) (5) (14) 373 - (203) In-process research and development 37 (37) - Restructuring 60 (60) - Provision for/(Benefit from) taxes on income (91) (46) 682 6 16 3 (66) 11 - 121 - 636 Net Earnings 1,738 1,280 2,220 31 69 11 (307) 44 - (121) - 4,965 Twelve Months Twelve Months Jan. 2, 2022 GAAP Intangible asset amortization Litigation expense, net Restructuring related Medical Device Regulation Other Jan. 2, 2022 Non-GAAP Cost of products sold 29,855 $ (4,661) (86) (85) 25,023 Selling, marketing and admin expenses 24,659 (24) 24,635 Research and development expense 14,714 (125) 14,589 Other (Income) / Expense 489 (36) (2,328) (135) 478 533 (67) - (1,066) In-process research and development 900 (900) - Restructuring 252 (252) - Provision for taxes on income 1,898 667 481 202 86 (98) (116) 44 15 1,090 - 4,269 Net Earnings 20,878 4,030 1,847 698 387 (380) (417) 190 52 (1,090) - 26,195 Twelve Months Twelve Months Jan. 3, 2021 GAAP Intangible asset amortization Litigation expense, net Restructuring related Medical Device Regulation Other Jan. 3, 2021 Non-GAAP Cost of products sold 28,427 $ (4,651) (89) (59) 23,628 Selling, marketing and admin expenses 22,084 (17) 22,067 Research and development expense 12,159 (68) 12,091 Other (Income) / Expense 2,899 (9) (5,112) (112) 1,073 547 (6) (720) In-process research and development 181 (181) - Restructuring 247 (247) - Provision for taxes on income 1,783 504 1,055 36 81 13 (108) 27 - 604 - 3,995 Net Earnings 14,714 4,156 4,057 145 367 (1,086) (439) 117 - (604) 6 21,433 (1) 2021 primarily includes gains on the divestitures of two Pharmaceutical brands outside of the United States. 2020 primarily includes a Contingent Consideration reversal of $1,148M related to the timing of certain developmental milestones associated with the Auris Health acquisition. Year to Date Johnson & Johnson and Subsidiaries GAAP to Non-GAAP Reconciliation $ in Millions Quarter to Date In-process research and development Acquisition, integration and divestiture related (Loss)/gain on securities Consumer Health separation costs Tax legislation and other tax related In-process research and development Acquisition, integration and divestiture related (Loss)/gain on securities Consumer Health separation costs Tax legislation and other tax related In-process research and development Acquisition, integration and divestiture related (1) (Loss)/gain on securities Consumer Health separation costs Tax legislation and other tax related In-process research and development Acquisition, integration and divestiture related (1) (Loss)/gain on securities Consumer Health separation costs Tax legislation and other tax related -- 6 of 6 --